BioCentury
ARTICLE | Finance

Ramping up Rubius

Why Rubius chose to beef up its platform rather than hurrying into the clinic

June 23, 2017 10:16 PM UTC

Rubius Therapeutics Inc. decided to delay its entry to the clinic to bring a broader set of compounds forward simultaneously. Now armed with an $120 million series B round, the biotech has the resources to do so.

The untranched round from Flagship Pioneering and undisclosed institutional investors was announced June 21...

BCIQ Company Profiles

Rubius Therapeutics Inc.